NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its first quarter revenues rose 9 percent thanks to strong sales of its XT-8 molecular diagnostics system.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $11.1 million, up from $10.1 million a year ago, and beating the consensus Wall Street estimate of $10.7 million.

Revenues from product sales were $11.0 million, with licensing and other revenues rounding out the total.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.